Form 4: Stoke Therapeutics CFO Thomas Leggett Acquires Stock Options and Restricted Stock Units

Chief Financial Officer Thomas Leggett of Stoke Therapeutics acquired stock options and restricted stock units on March 20, 2025, according to a Form 4 filing with the SEC.

Summary

• Thomas Leggett, the Chief Financial Officer of Stoke Therapeutics, acquired stock options and restricted stock units on March 20, 2025.
• The filing, a Form 4, was submitted to the Securities and Exchange Commission (SEC).
• Leggett acquired options to purchase 89,000 shares of common stock at an exercise price of $8.33.
• These options vest monthly starting April 15, 2025, and expire on March 19, 2035.
• Leggett also acquired 59,000 restricted stock units (RSUs), each representing one share of Stoke Therapeutics' common stock.
• These RSUs vest annually beginning on March 15, 2026.
• The reporting person's continued service to the issuer through each vesting date is required for both the options and RSUs to vest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the company's future. There are no explicitly negative aspects in the filing.

Positives

• The acquisition of stock options and RSUs by the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued service from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that the CFO is incentivized to contribute to the company's growth through equity-based compensation.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to attract and retain talent.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and amounts granted are generally aligned with industry norms for CFO-level positions.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with theirs.
• Employees may see this as a sign of stability and commitment from the leadership team.

Key Dates

Keywords

Form 4, Stoke Therapeutics, Stock Options, Restricted Stock Units, Insider Trading, Thomas Leggett, STOK, CFO, SEC